Literature DB >> 7072532

Characteristics of giant pituitary adenomas.

E Grote.   

Abstract

An analysis of 21 giant pituitary adenomas is presented. Giant pituitary adenomas with a diameter of more than four cm mostly perforate dura and diaphragm, invade the cavernous sinus, and spread extradurally into anterior and middle cranial fossae or into the frontal or temporal lobes. Endocrinologically, a third are prolactinomas, and a half are non-secreting tumours leading to pituitary failure. Clinical, radiological, and operative characteristics lead to the conclusions that multishaped dura-penetrating extension is not due to locally destructive growth, but is the result of late diagnosis. Because radical cure by operation and radiotherapy is hardly likely, early operative treatment is necessary even when an excellent endocrinological response to medical therapy is present.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7072532     DOI: 10.1007/bf01406303

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

Review 1.  Ultrastructure of human sella tumors. Correlations of clinical findings and morphology.

Authors:  A M Landolt
Journal:  Acta Neurochir (Wien)       Date:  1975       Impact factor: 2.216

2.  [Classification and pathogenesis of pituitary adenomas in humans and animal experiments].

Authors:  W Saeger
Journal:  Fortschr Med       Date:  1977-06-09

3.  Trans-sphenoidal surgery of pituitary fossa tumors with televised radiofluoroscopic control.

Authors:  J Hardy; S M Wigser
Journal:  J Neurosurg       Date:  1965-12       Impact factor: 5.115

  3 in total
  9 in total

1.  Aggressive giant pituitary adenoma presenting as a nasopharyngeal mass: magnetic resonance imaging and pathologic findings.

Authors:  T P Ravichandran; R Bakshi; R R Heffner; K J Gibbons; V E Bates; D J Durante; W R Kinkel
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery.

Authors:  Christoph P Hofstetter; Michael J Nanaszko; Lynn L Mubita; John Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

4.  A simple method of estimating the size of large pituitary adenomas.

Authors:  A P Jones; A J Keogh
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

5.  Giant pituitary adenomas.

Authors:  H W Pia; E Grote; G Hildebrandt
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

6.  Intraoperative magnetic resonance imaging-guided transsphenoidal surgery for giant pituitary adenomas.

Authors:  Fabian Baumann; Christoph Schmid; René-Ludwig Bernays
Journal:  Neurosurg Rev       Date:  2009-10-13       Impact factor: 3.042

7.  Three-dimensional volumetric measurements in defining endoscope-guided giant adenoma surgery outcomes.

Authors:  Muhammad Omar Chohan; Ariana M Levin; Ranjodh Singh; Zhiping Zhou; Carlos L Green; Jacob J Kazam; Apostolos J Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

8.  AKU Giant Pituitary Adenoma Score: A Novel Scoring System to Predict the Outcomes of Surgery for Giant Pituitary Adenomas.

Authors:  Syed A Enam; Sanam M Ghazi; Muhammad F Raghib; Adnan Salim; Shiraz Hashmi; Fauzan Hashmi; Saad B Anis; Muhammad Bilal Tariq; Meher Angez; Shahzad Shamim; Ahsan A Khan
Journal:  Cureus       Date:  2022-09-16

9.  Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study.

Authors:  Zhiyong Chen; Bin Hu; Yajuan Feng; Zongming Wang; Xiaobing Jiang; Yunjiu Cheng; Dongsheng He; Dimin Zhu; Zheng Xiao; Haijun Wang; Zhigang Mao
Journal:  Ther Clin Risk Manag       Date:  2018-12-28       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.